About Aquestive Therapeutics
Aquestive Therapeutics is a publicly listed company based in Warren (United States) founded in 2005. Developer of small molecule-based therapeutics for the treatment of CNS diseases. Aquestive Therapeutics has raised $57.06 million across 8 funding rounds from investors including RTW Investments, Perceptive Advisors and Madryn Asset Management. The company has 142 employees. Its website aquestive.com draws about 15 thousand monthly visits. Aquestive Therapeutics offers products and services including PharmFilm Technology, Libervant, and Anaphylm. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Aquestive Therapeutics, Inc. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Aquestive Therapeutics was founded in 2005 and is headquartered in Warren, United States. Focus is placed on the biotechnology sector, where small molecule-based treatments for central nervous system disorders are developed. Proprietary PharmFilm technology is employed to create a range of products, including Libervant for seizure management, AQST-108 for severe allergic reactions, and AQST-305 for acromegaly and neuroendocrine tumors, with additional candidates in the pipeline.
- Headquarters Warren, United States
- Employees 142
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website aquestive.com
- Social LinkedIn X YouTube
- Legal Name Aquestive Therapeutics, Inc.
- Annual Revenue$44.55 M (USD)-22.61as on Dec 31, 2025
- Net Profit-$83.78 M (USD)-89.83as on Dec 31, 2025
- EBITDA-$69.09 M (USD)-129.9as on Dec 31, 2025
- Total Equity Funding$57.06M (USD)
in 8 rounds
- Latest Funding Round$75M (USD), Post-IPO
Aug 2025
- InvestorsRTW Investments
& 2 more
- Employee Count142
Products & Services of Aquestive Therapeutics
Aquestive Therapeutics offers a comprehensive portfolio of products and services, including PharmFilm Technology, Libervant, and Anaphylm.
Platform for administering medications via oral film for enhanced absorption
Buccal film treatment for seizure clusters in pediatric patients
Sublingual film for rapid epinephrine delivery in anaphylaxis
Apps and channels of Aquestive Therapeutics
its YouTube channel Aquestive Therapeutics has 79 subscribers and 4 videos.
Videos from Aquestive Therapeutics
The most watched videos on Aquestive Therapeutics's YouTube channel, Aquestive Therapeutics (79 subscribers). Click a video to play it here.
More on Aquestive Therapeutics.
Funding Insights of Aquestive Therapeutics
Aquestive Therapeutics has successfully raised a total of $57.06M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $75 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $57.06M
- Total Rounds 8
- Last Round Post-IPO — $75M
- First Round $38M
(Dec 2006)
- Investors Count 3
All 8 funding rounds of Aquestive Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2025 | $75M | Post-IPO | – | – | |
| Jul 2019 | $70M | Debt – Conventional | – | – | |
| Apr 2018 | $9.06M | Series A | – | – | – |
| Aug 2016 | $50M | Debt – Conventional | – | – | |
| Sep 2008 | $10M | Private Equity Round | – | – | – |
| Jun 2008 | $10M | Debt – Conventional | – | – | – |
| Mar 2008 | $2.5M | Debt – Conventional | – | – | – |
| Dec 2006 | $38M | Private Equity Round | – | – | – |
3 investors in total: 3 institutional.
Investors in Aquestive Therapeutics
Aquestive Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include RTW Investments, Perceptive Advisors and Madryn Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Diversified asset management is provided by the firm. | 2017 | madrynlp.com | New York, United States |
Investor details for Aquestive Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aquestive Therapeutics
51 people are tracked at Aquestive Therapeutics (20 in leadership, 14 in board & advisors, 17 in team); the tracked headcount is 142.
| Name | Role | Group |
|---|---|---|
Daniel Barber | CEO, President & Director | Leadership |
Chris Knowles | Vice President Marketing | Leadership |
Eric Judka | Marketing Director | Leadership |
Vincent Buono | Vice President, Research And Development | Leadership |
Trish McAdoo | Vice President; Market Access, Trade & Patient Services | Leadership |
Mark Schobel | Chief Innovation & Technology Officer | Leadership |
Ernie Toth | CFO | Leadership |
Milosz Blyszczek | Senior Director Clinical Operations | Leadership |
Andrew Bruce | Director Of Global Supply Chain | Leadership |
Sherry Korczynski | Chief Commercial Officer (cco) | Leadership |
Stephanie Varjan | Director, Strategic Development & Advocacy | Leadership |
Matt Schnecke | Global Supply Chain Manager | Pharmaceutical CMO Leader | Leadership |
Melissa Milton | Sr. Director Of Engineering & Operations | Leadership |
Amy Santos | Vice President, Global Quality And Compliance | Leadership |
Kimberly Lorenz | Director Of Quality Assurance | Leadership |
Joseph Crusco | Director Business Development | Leadership |
Phenix Mayas | Director Of Information Technology Of Corporate Systems | Leadership |
Matthew S. Green | Vice President, Head Of Finance | Leadership |
Melina Cioffi | Senior Vice President | Leadership |
Shawn Berg | Director Clinical Development | Leadership |
31 more people are available in the full profile.
Complete people profiles for Aquestive Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aquestive Therapeutics
Aquestive Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AQST in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Jul 2018
- Listed onNASDAQ: AQST
- Listed entityAquestive Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS03843E1047
- Share price$4.67 (-2.91% on the day) · 2026-10-13
- Market capitalisation$586.1M
- EPS (diluted, trailing year)$-0.65
- Volume (last session)1,400,435
Financials of Aquestive Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $44.5M | -$83.8M | -$69.1M |
| 2024 | $57.6M | -$44.1M | -$30.1M |
| 2023 | $50.6M | -$7.9M | -$13.5M |
| 2022 | $47.7M | -$54.4M | -$39.7M |
| 2021 | $50.8M | -$70.5M | -$31.7M |
Detailed financial statements for Aquestive Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Aquestive Therapeutics
4 dated milestones of Aquestive Therapeutics across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Aquestive Therapeutics is founded.
- Funding First funding round of $38.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $75.0M.
Competitors of Aquestive Therapeutics
Aquestive Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Aquestive Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aquestive Therapeutics
The website of Aquestive Therapeutics (aquestive.com) receives about 15.5K visits a month and ranks #1,272,326 among all websites worldwide, #1,620 in Biotechnology and Pharmaceuticals.
- Monthly visits15.5K
▼ 11.1% vs previous month
- Unique visitors5.8K
per month
- Global rank#1,272,326
among all websites
- Category rank#1,620
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit3.1
- Average visit1 min 14 sec
- DevicesDesktop 63% · Mobile 37%
Websites whose visitors overlap most with Aquestive Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hcplive.com | 100% | #212,282 | View details | ||
thepharmaletter.com | thepharmaletter.com | 100% | #486,864 | – | |
jacionline.org | jacionline.org | 100% | #194,118 | – | |
healio.com | healio.com | 67% | #72,463 | – |
Top companies in Neurology
3 companies that operate in the same segment as Aquestive Therapeutics (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aquestive Therapeutics
Complete news archive for Aquestive Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aquestive Therapeutics
Aquestive Therapeutics was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Aquestive Therapeutics is headquartered in Warren, United States. It is registered at Warren, Michigan, United States.
Aquestive Therapeutics is a funded company, having raised a total of $57.06M across 8 funding rounds to date. The company's 1st funding round was a Private Equity Round of $38M, raised on Dec 2006.
Aquestive Therapeutics has 142 employees.
Annual revenue of Aquestive Therapeutics is $44.55M as on Dec 31, 2025.
Aquestive Therapeutics was founded in 2005 and is headquartered in Warren, United States. Focus is placed on the biotechnology sector, where small molecule-based treatments for central nervous system disorders are developed. Proprietary PharmFilm technology is employed to create a range of products, including Libervant for seizure management, AQST-108 for severe allergic reactions, and AQST-305 for acromegaly and neuroendocrine tumors, with additional candidates in the pipeline.
Aquestive Therapeutics's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Aquestive Therapeutics offers PharmFilm Technology, Libervant, and Anaphylm.
Yes, Aquestive Therapeutics is publicly traded on NASDAQ under the ticker symbol AQST.
Aquestive Therapeutics has 3 investors. Key investors include RTW Investments, Perceptive Advisors, and Madryn Asset Management.
Aquestive Therapeutics operates through Aquestive Therapeutics, Inc..